PMID: 11920528Mar 29, 2002Paper

Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma

Cancer
Andrés Rodríguez-AlonsoJosé Luis Nogueira-March

Abstract

Determination of prognosis factors associated with survival, recurrence, progression, and development of metastasis in T1 and T2a transitional cell carcinoma (TCC) of the bladder is discussed. A study was conducted of a group of 210 patients with primary bladder TCC at classification T1 (n = 175) and T2aN0M0 (n = 35). A total of 177 variables were studied in each patient. The monoclonal antibodies used were the following: DO7 (p53) and MIB-1 (Ki-67). Prognosis was obtained using Kaplan-Meier methodology and Cox proportional hazards model. The average follow-up period was 6.7 years. Cancer-related survival rates at 5 and 10 years were 82.96% and 74.78%, respectively. The independent survival variables were the following: age and expression of p53. Recurrence free survival at 5 and 10 years stood at 51.80% and 42.71%, respectively. The independent recurrence variables were T2a classification, tumor multifocality, tumor size of greater than 3 cm, carcinoma in situ in random biopsy, and expression of Ki-67. Progression free survival rates at 5 and 10 years were 75.31% and 69.16%, respectively. The independent progression variables were age, T2a classification, and expression of p53. Metastasis free survival rates at 5 and 10 years ...Continue Reading

References

Jan 1, 1987·Urologia Internationalis·M TakashiY Ohno
Jul 1, 1983·The Journal of Urology·A S NarayanaD A Culp
Nov 10, 1994·The New England Journal of Medicine·D EsrigR J Cote
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A KuczykU Jonas
Aug 28, 1998·The Journal of Urology·J P SteinR J Cote
Dec 22, 1999·The Journal of Urology·F Millán-RodríguezJ Vicente-Rodríguez

❮ Previous
Next ❯

Citations

Sep 28, 2004·Pathology Oncology Research : POR·Zahra AmirghofranZahra Malek-Hosseini
Aug 27, 2002·Current Treatment Options in Oncology·Fabio Calabrò, Cora N Sternberg
Apr 22, 2009·AJR. American Journal of Roentgenology·Haruo WatanabeNoriyuki Moriyama
Feb 2, 2013·Journal of Mid-life Health·Abbas RezaianzadehNarges Mohammadsalehi
Nov 28, 2008·BJU International·Matthew R BraaschMichael A O'Donnell
Jul 10, 2004·International Journal of Urology : Official Journal of the Japanese Urological Association·Akinori SatohSo Nakamura
Apr 1, 2011·International Journal of Urology : Official Journal of the Japanese Urological Association·Sentai DingHiroyuki Nishiyama
Jun 18, 2011·Scandinavian Journal of Urology and Nephrology·Georg JanckeStaffan Jahnson
Jul 23, 2020·Journal of Cellular Physiology·Hanieh AzariMohammad Shekari
Apr 26, 2003·Virchows Archiv : an International Journal of Pathology·Burkhard HelpapMichael J Droller
Jan 1, 2007·Biomarker Insights·Andrea Brunner, Alexandar Tzankov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Related Papers

Scandinavian Journal of Urology and Nephrology
Suresh K Gupta, Nigel J Parr
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
David J Vaughn
© 2022 Meta ULC. All rights reserved